Certain statements on this website are forward-looking statements, including those that discuss strategies, goals, outlook or other non-historical matters; or project revenues, income, returns or other financial measures. These forward-looking statements speak only as of the date on which they are made, and Rich Pharmaceuticals, Inc. undertakes no obligation to update or revise any forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those contained in the statements, including the risks and uncertainties listed under “Forward-looking Information” and “Risk Factors” in Textron’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
Rich Pharmaceuticals Retains Experienced Contract Research Organization to Assist with Clinical Trials
Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson’s Disease: Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders
Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials